2009
DOI: 10.2174/187152809787582462
|View full text |Cite
|
Sign up to set email alerts
|

Kounis Syndrome Following Beta-Lactam Antibiotic Use: Review of Literature

Abstract: Patients with anaphylaxis can present with acute coronary syndrome secondary to either vasospasm or acute plaque rupture and thrombus formation. The typical patient is a man with cutaneous, respiratory and cardiac symptoms and with ST segment elevation in inferior leads. The pathogenesis involves histamine and other mast cell mediators. Management should include therapy for anaphylaxis and vasospasmolytics. The use of epinephrine requires caution.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
55
0
5

Year Published

2010
2010
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 68 publications
(61 citation statements)
references
References 23 publications
1
55
0
5
Order By: Relevance
“…Hypersensitivity reactions following implantation of drug-eluting stents and stent thrombosis which may be considered as a manifestation of Kounis syndrome, a type III variant of Kounis syndrome has been introduced [5,6]. Drugs implicated with Kounis syndrome include catecholamines (epinephrine, norepinephrine, isoproterenol, dopamine, dobutamine); parasympathomimetic agents (acetylcholine, methacholine, pilocarpine); anticholinesterase agents (neostigmine); beta-blockers; anaesthetic agents (etomidate); antibiotics (ciprofloxacin, amoxicillin, ampicillin, cephalosporins, vancomycin); NSAIDS; chemotherapeutic drugs; thrombolytic agents; withdrawal from chronic exposure to nitroglycerine, cocaine, smoking and alcohol [7][8][9][10]. No biomarker accurately predicts the risk of Kounis syndrome, albeit recent reports link elevated serum tryptase levels to increased susceptibility to allergic reactions as well as asymptomatic ACS.…”
Section: Discussionmentioning
confidence: 99%
“…Hypersensitivity reactions following implantation of drug-eluting stents and stent thrombosis which may be considered as a manifestation of Kounis syndrome, a type III variant of Kounis syndrome has been introduced [5,6]. Drugs implicated with Kounis syndrome include catecholamines (epinephrine, norepinephrine, isoproterenol, dopamine, dobutamine); parasympathomimetic agents (acetylcholine, methacholine, pilocarpine); anticholinesterase agents (neostigmine); beta-blockers; anaesthetic agents (etomidate); antibiotics (ciprofloxacin, amoxicillin, ampicillin, cephalosporins, vancomycin); NSAIDS; chemotherapeutic drugs; thrombolytic agents; withdrawal from chronic exposure to nitroglycerine, cocaine, smoking and alcohol [7][8][9][10]. No biomarker accurately predicts the risk of Kounis syndrome, albeit recent reports link elevated serum tryptase levels to increased susceptibility to allergic reactions as well as asymptomatic ACS.…”
Section: Discussionmentioning
confidence: 99%
“…13 Hundreds of cases of Kounis syndrome have been described since, including several case series. [32][33][34][35] Kounis syndrome has been described secondary to a large number of drugs, of various classes (e.g. antibiotics, muscle relaxants, anti-neoplastics, contrast media, NSAIDS, thrombolytics etc.).…”
Section: Aetiologymentioning
confidence: 99%
“…Actually in literature more than 30 cases of KS betalactamsinduced have been reported [4] and amoxicillin is the most frequently involved molecule, followed by Ampicillin, Penicillin G and various cephalosporins, but no case of KS due to piperacillin/tazobactam infusion have been never previously reported.…”
Section: Contents Lists Available At Sciencedirectmentioning
confidence: 99%